Summary & Overview
HCPCS Level II J1410: Injection, Estrogen Conjugated, 25 mg
HCPCS Level II code J1410 denotes an injectable dose of conjugated estrogens, billed per 25 mg. The code captures administration of parenteral estrogen therapy commonly used in menopausal symptom management, hypoestrogenic states, and certain hormone-related conditions. Nationally, accurate capture of this code is important for drug utilization reporting, outpatient infusion billing, and payer reimbursement policies for hormone therapies.
Key payers examined include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of how J1410 is used clinically, typical sites of service where the injection is given, and the payer context relevant to coverage and billing workflows. The publication outlines benchmarks for utilization and reimbursement trends where available, summarizes notable policy considerations affecting coverage of injectable estrogen products, and provides clinical context to support correct coding.
Data not available in the input for associated taxonomies, ICD-10 diagnoses, related codes, and service line.
Billing Code Overview
HCPCS Level II code J1410 represents an injection of estrogen conjugated, billed per 25 mg unit. This code describes a pharmaceutical administration service for conjugated estrogens used in hormonal therapy.
-
Service type: Injectable estrogen therapy
-
Typical site of service: Outpatient clinic, physician office, or ambulatory infusion setting where intramuscular or other parenteral hormone injections are administered.
Data not available in the input for associated taxonomies, ICD-10 diagnoses, related codes, and service line.
Clinical & Coding Specifications
Clinical Context
A typical patient is a postmenopausal woman presenting for hormone therapy management due to vasomotor symptoms (hot flashes), vulvovaginal atrophy, or osteoporosis prevention and who receives an intramuscular dose of conjugated estrogens. In the outpatient infusion or procedure area, the clinician confirms indication, documents informed consent, reviews contraindications (history of thromboembolic disease, estrogen-sensitive malignancy), and verifies medication and dose. A nurse prepares a syringe containing J1410 (injection, estrogen conjugated, per 25 mg) and administers the intramuscular injection, typically in the gluteal or deltoid muscle, with standard infection control and post-injection observation. Billing captures the drug unit quantity by 25 mg increments and any applicable modifier(s) reflecting circumstances of the service (for example, a separate identifiable evaluation and management service or a partially reduced service).
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
25 | Significant, separately identifiable evaluation and management service by the same physician on the same day of the procedure | Use when an E/M visit (office or other outpatient) is performed and documented separately from the injection encounter |